✦ LIBER ✦

Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity (II): Optimization of the C3 Amino Substituent

✍ Scribed by Hirst, Gavin C.; Aquino, Christopher; Birkemo, Lawrence; Croom, Dallas K.; Dezube, Milana; Dougherty,, Robert W.; Ervin, Gregory N.; Grizzle, Mary K.; Henke, Brad; James, Michael K.; Johnson, Michael F.; Momtahen, Tanya; Queen, Kennedy L.; Sherrill, Ronald G.; Szewczyk, Jerzy; Willson, Timothy M.; Sugg, Elizabeth E.

Book ID: 126245118
Publisher: American Chemical Society
Year: 1996
Tongue: English
Weight: 243 KB
Volume: 39
Category: Article
ISSN: 0022-2623
DOI: 10.1021/jm9601664

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ChemInform Abstract: Discovery of 1,5-Be

ChemInform Abstract: Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK- A) Receptor Agonist Activity (II): Optimization of the C3 Amino Substituent.

✍ G. C. HIRST; C. AQUINO; L. BIRKEMO; D. K. CROOM; M. DEZUBE; R. W. JUN. DOUGHERTY 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 34 KB 👁 1 views

Discovery of 1,5-Benzodiazepines with Pe

Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger”

✍ Aquino, Christopher J.; Armour, Duncan R.; Berman, Judd M.; Birkemo, Larry S.; C 📂 Article 📅 1996 🏛 American Chemical Society 🌐 English ⚖ 230 KB

5-[(3-Nitropyrid-2-yl)amino]indoles: Nov

5-[(3-Nitropyrid-2-yl)amino]indoles: Novel Serotonin Agonists with Selectivity for the 5-HT1D Receptor. Variation of the C3 Substituent on the Indole Template Leads to Increased 5-HT1D Receptor Selectivity

✍ Macor, John E.; Blank, David H.; Fox, Carol B.; Lebel, Lorraine A.; Newman, Mich 📂 Article 📅 1994 🏛 American Chemical Society 🌐 English ⚖ 498 KB

Discovery of N-benzyl-2-[(4S)-4-(1H-indo

Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

✍ Richard L. Elliott; Kimberly O. Cameron; Janice E. Chin; Jeremy A. Bartlett; Ele 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 598 KB

We describe the design, synthesis, and structure-activity relationships of triazolobenzodiazepinone CCK1 receptor agonists. Analogs in this series demonstrate potent agonist activity as measured by in vitro and in vivo assays for CCK1 agonism. Our efforts resulted in the identification of compound 4

ChemInform Abstract: Discovery of N-Benz

ChemInform Abstract: Discovery of N-Benzyl-2- [(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H- [1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide (I), an Orally Active, Gut-Selective CCK1 Receptor Agonist for the Potential Treatment of Obesity.

✍ Kimberly O. Cameron; et al. et al. 📂 Article 📅 2011 🏛 John Wiley and Sons ⚖ 23 KB 👁 1 views

Discovery and Structure−Activity Relatio

Discovery and Structure−Activity Relationship of (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a Selective Serotonin 5-HT2C Receptor Agonist for the Treatment of Obesity

✍ Smith, Brian M.; Smith, Jeffrey M.; Tsai, James H.; Schultz, Jeffrey A.; Gilson, 📂 Article 📅 2008 🏛 American Chemical Society 🌐 English ⚖ 154 KB